$203.73
1.87%
Downside
Day's Volatility :2.27%
Upside
0.42%
27.35%
Downside
52 Weeks Volatility :50.99%
Upside
32.54%
Period | Penumbra Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 7.82% | 5.1% | 0.0% |
6 Months | -19.44% | 4.9% | 0.0% |
1 Year | -29.63% | 16.6% | 0.0% |
3 Years | -24.59% | 13.2% | -22.3% |
Market Capitalization | 7.9B |
Book Value | $29.9 |
Earnings Per Share (EPS) | 0.35 |
PE Ratio | 582.09 |
PEG Ratio | -62.27 |
Wall Street Target Price | 201.33 |
Profit Margin | 1.26% |
Operating Margin TTM | -1.34% |
Return On Assets TTM | 3.32% |
Return On Equity TTM | 1.28% |
Revenue TTM | 1.1B |
Revenue Per Share TTM | 29.33 |
Quarterly Revenue Growth YOY | 14.499999999999998% |
Gross Profit TTM | 535.2M |
EBITDA | 105.6M |
Diluted Eps TTM | 0.35 |
Quarterly Earnings Growth YOY | 0.27 |
EPS Estimate Current Year | 2.62 |
EPS Estimate Next Year | 3.61 |
EPS Estimate Current Quarter | 0.56 |
EPS Estimate Next Quarter | 0.88 |
What analysts predicted
Downside of 1.18%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 444.9M | ↑ 33.31% |
Net Income | 6.6M | ↑ 41.74% |
Net Profit Margin | 1.48% | ↑ 0.08% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 547.4M | ↑ 23.03% |
Net Income | 48.5M | ↑ 634.1% |
Net Profit Margin | 8.85% | ↑ 7.37% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 560.4M | ↑ 2.38% |
Net Income | -19.3M | ↓ 139.74% |
Net Profit Margin | -3.44% | ↓ 12.29% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 747.6M | ↑ 33.4% |
Net Income | 2.6M | ↓ 113.62% |
Net Profit Margin | 0.35% | ↑ 3.79% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 847.1M | ↑ 13.32% |
Net Income | -2.0M | ↓ 176.32% |
Net Profit Margin | -0.24% | ↓ 0.59% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 24.95% |
Net Income | 91.0M | ↓ 4643.16% |
Net Profit Margin | 8.59% | ↑ 8.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 241.4M | ↑ 9.12% |
Net Income | 8.6M | ↑ 120.84% |
Net Profit Margin | 3.55% | ↑ 1.8% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 261.5M | ↑ 8.33% |
Net Income | 19.0M | ↑ 121.44% |
Net Profit Margin | 7.25% | ↑ 3.7% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 270.9M | ↑ 3.61% |
Net Income | 9.2M | ↓ 51.4% |
Net Profit Margin | 3.4% | ↓ 3.85% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 284.7M | ↑ 5.07% |
Net Income | 54.2M | ↑ 488.43% |
Net Profit Margin | 19.05% | ↑ 15.65% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 278.7M | ↓ 2.12% |
Net Income | 11.0M | ↓ 79.71% |
Net Profit Margin | 3.95% | ↓ 15.1% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 299.4M | ↑ 7.45% |
Net Income | -60.2M | ↓ 647.17% |
Net Profit Margin | -20.11% | ↓ 24.06% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 515.0M | ↑ 8.04% |
Total Liabilities | 92.6M | ↑ 21.42% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 665.9M | ↑ 29.3% |
Total Liabilities | 180.3M | ↑ 94.71% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 823.0M | ↑ 23.59% |
Total Liabilities | 185.2M | ↑ 2.72% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 51.19% |
Total Liabilities | 290.3M | ↑ 56.77% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 10.18% |
Total Liabilities | 372.0M | ↑ 28.14% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 13.53% |
Total Liabilities | 377.4M | ↑ 1.43% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↑ 1.78% |
Total Liabilities | 370.8M | ↓ 0.32% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↑ 2.67% |
Total Liabilities | 366.0M | ↓ 1.31% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↑ 2.5% |
Total Liabilities | 364.2M | ↓ 0.48% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↑ 5.99% |
Total Liabilities | 377.4M | ↑ 3.6% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↑ 1.51% |
Total Liabilities | 376.3M | ↓ 0.28% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↓ 2.87% |
Total Liabilities | 373.3M | ↓ 0.79% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 28.8M | ↑ 127.0% |
Investing Cash Flow | -385.0K | ↓ 99.5% |
Financing Cash Flow | -9.8M | ↓ 109.41% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 26.7M | ↓ 7.48% |
Investing Cash Flow | -12.7M | ↑ 3201.56% |
Financing Cash Flow | -9.0M | ↓ 8.72% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.2M | ↓ 224.73% |
Investing Cash Flow | -104.1M | ↑ 719.36% |
Financing Cash Flow | 134.9M | ↓ 1605.94% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 9.5M | ↓ 128.58% |
Investing Cash Flow | -21.7M | ↓ 79.13% |
Financing Cash Flow | 836.0K | ↓ 99.38% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -55.7M | ↓ 685.78% |
Investing Cash Flow | 54.8M | ↓ 352.08% |
Financing Cash Flow | 11.6M | ↑ 1290.19% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 13.1M | ↑ 881.97% |
Investing Cash Flow | 10.7M | ↓ 80.45% |
Financing Cash Flow | 1.4M | ↓ 76.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 17.1M | ↑ 30.24% |
Investing Cash Flow | -6.7M | ↓ 162.28% |
Financing Cash Flow | 8.7M | ↑ 531.83% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 30.8M | ↑ 80.38% |
Investing Cash Flow | -40.4M | ↑ 504.95% |
Financing Cash Flow | 212.0K | ↓ 97.56% |
Sell
Neutral
Buy
Penumbra Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Penumbra Inc | 24.5% | -19.44% | -29.63% | -24.59% | 49.61% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Penumbra Inc | 582.09 | 582.09 | -62.27 | 2.62 | 0.01 | 0.03 | NA | 29.9 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Penumbra Inc | Buy | $7.9B | 49.61% | 582.09 | 1.26% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Penumbra Inc
Revenue is up for the last 2 quarters, 278.65M → 299.40M (in $), with an average increase of 6.9% per quarter
Netprofit is down for the last 3 quarters, 54.21M → -60.2M (in $), with an average decrease of 363.4% per quarter
In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 81.0%
In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 105.5%
FMR Inc
BlackRock Inc
Vanguard Group Inc
T. Rowe Price Associates, Inc.
Champlain Investment Partners, LLC
State Street Corporation
penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.
Organization | Penumbra Inc |
Employees | 4200 |
CEO | Mr. Adam Elsesser |
Industry | Health Technology |
Assetmark Financial Holdings Inc
$203.73
-0.15%
Fidelity Msci Health Care Etf
$203.73
-0.15%
Texas Capital Bancshares Inc.
$203.73
-0.15%
Primerica, Inc.
$203.73
-0.15%
Thor Industries Inc.
$203.73
-0.15%
Qifu Technology Inc
$203.73
-0.15%
Crinetics Pharmaceuticals Inc
$203.73
-0.15%
Hercules Capital Inc
$203.73
-0.15%
Janus Henderson Mortgage-backed Securities Etf
$203.73
-0.15%